FDA APPROVES New Cancer Treatment – Finally!

FDA approves groundbreaking new therapy for rare ovarian cancer that resists conventional treatments, giving hope to thousands of American women.

At a Glance

  • Avmapki Fakzynja, a new combination therapy from Verastem Oncology, becomes the first FDA-approved treatment specifically for KRAS-mutated low-grade serous ovarian cancer
  • The therapy showed a 44% response rate in clinical trials for a cancer type that typically resists chemotherapy
  • Approximately 6,000-8,000 American women live with this rare form of ovarian cancer
  • The treatment will be available within a week at $48,500 for a 28-day prescription

First Targeted Treatment for Rare Ovarian Cancer

The FDA has granted accelerated approval to Verastem Oncology’s Avmapki Fakzynja co-pack, marking a significant medical breakthrough for patients with recurrent KRAS-mutated low-grade serous ovarian cancer (LGSOC). This approval represents the first and only FDA-approved treatment specifically designed for this rare cancer type, which affects between 6,000 and 8,000 women across the United States. The therapy combines two medications – avutometinib and defactinib – that work together to inhibit multiple cancer pathways that promote tumor growth and resistance to treatment.

For patients who have battled through multiple rounds of conventional therapies with limited success, this approval offers a new, targeted approach. LGSOC is particularly challenging to treat because it responds poorly to standard chemotherapy regimens, which has left patients with few effective options until now. The combination therapy specifically targets cancer cells with KRAS mutations, addressing the underlying molecular mechanisms that drive this disease.

Promising Clinical Results

The FDA based its approval on results from a mid-stage clinical trial involving 57 patients with KRAS-mutated recurrent LGSOC who had received at least one prior systemic therapy, including a platinum-based regimen.

The study demonstrated impressive efficacy with a confirmed overall response rate of 44%, meaning nearly half of the patients experienced significant tumor shrinkage. Furthermore, the duration of response ranged from 3.3 to 31.1 months, indicating lasting benefits for many patients.

Dan Paterson, a representative from Verastem Oncology, further emphasized that this approval represents “not only the first-ever FDA-approved treatment specifically for this rare cancer but also a new day for people living with this disease who have been in desperate need of new treatment options.” The company’s shares increased by 5% following the announcement, reflecting investor confidence in the therapy’s potential impact.

Treatment Details and Availability

The Avmapki Fakzynja co-pack will be available in the United States within one week, priced at $48,500 for a 28-day prescription. The recommended dosing regimen includes avutometinib 3.2 mg orally twice weekly and defactinib 200 mg orally twice daily for the first three weeks of each four-week treatment cycle. This specialized dosing schedule aims to maximize efficacy while managing side effects.

Common adverse reactions reported during clinical trials include nausea, fatigue, rash, and diarrhea. Patients should be aware of potential serious side effects such as ocular disorders, skin toxicities, liver problems (hepatotoxicity), rhabdomyolysis (muscle breakdown), and possible fetal harm during pregnancy. Healthcare providers are encouraged to report serious adverse events to the FDA’s MedWatch Reporting System to continue monitoring the therapy’s safety profile.

Expedited Approval Process

The FDA utilized several special programs to expedite the review and approval of this much-needed treatment. The application received priority review status, breakthrough therapy designation, and orphan drug designation, highlighting the significant unmet medical need in this patient population. The review process also employed the Real-Time Oncology Review pilot program and the Assessment Aid to streamline the FDA’s evaluation of the therapy’s benefits and risks.

For LGSOC patients, who represent a small subset of the approximately 20,000 women diagnosed with ovarian cancer annually in the United States, this approval represents a crucial advancement in personalized medicine. By targeting specific genetic mutations found in their tumors, Avmapki Fakzynja offers a more precise treatment approach than conventional chemotherapy, potentially leading to better outcomes with fewer side effects for this historically underserved patient population.

RELATED ARTICLESMORE FROM AUTHOR